Online inquiry

IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9696MR)

This product GTTS-WQ9696MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KLRK1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_007360.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 22914
UniProt ID P26718
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9696MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5803MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ11483MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ12993MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ11270MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ14805MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ15732MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ1559MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-041
GTTS-WQ1533MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW